… Lung cancer is the leading cause of cancer deaths worldwide. Approximately 400,000 new
cases of lung cancer are diagnosed every year in Europe; lung … cancers in men. Citation1 …

… advanced pancreatic cancer. The oral administration and manageable toxicity of erlotinib,
along … : This review summarizes safety data from major clinical trials of erlotinib in patients with …

… safety of erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based
observational study. The study involved 307 patients treated with erlotinib … received erlotinib …

… There were no unexpected safety findings relating to erlotinib in this study. As the prespecified
expected treatment-related AEs were not recorded (unless they resulted in premature …

… The aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese
patients with previously treated non-small cell lung cancer (NSCLC). Available tumor biopsy …

… that in this analysis of elderly patients receiving erlotinib in the first-line setting, no new
safety signals were identified. The most common AE seen with erlotinib is skin rash, but this is …

… on 4068 concentration samples from 1047 patients receiving erlotinib as a single agent or in
… erlotinib exposure in non-small cell lung cancer patients treated with single-agent erlotinib. …

… III study comparing gefitinib with erlotinib. It did not demonstrate statistical non inferiority of
gefitinib in terms of PFS compared with erlotinib [7]. The LUX-Lung 7 trial compared afatinib …

… 409 patients were included in the safety population: 196 in the erlotinib group and 213 in
the chemotherapy group. 46 (23%) of 196 patients in the erlotinib group were treated for 0–30 …

… The safety population comprised all patients who received erlotinib and had a case report
… included in the safety population, except those where erlotinib therapy was prescribed off-…